Results
Forty-two patients from April 2020-May 2022, with a mean age of 6.8
years were reported from Argentina, Switzerland, Netherlands, Canada,
France, Italy, Australia and Turkey. 34 patients (81%) had a type C,
EA-TEF. 30 had respiratory comorbidities, 14 had associated cardiac
malformations and 14 had a history of recurrent anastomotic stricture.
Reported medications included proton-pump inhibitors (n=14), inhaled
bronchodilators (n=3) and inhaled corticosteroids (n=4).
Six patients (14%) were hospitalised. Three required respiratory
support and one required extra-corporal membranous oxygenation. There
were no deaths.
Respiratory, cardiac and gastrointestinal comorbidities were not
associated with increased risk of hospitalization. Concomitant
medication at time of infection was associated with increased risk for
hospitalization with SARS-CoV-2 infection (p=0.0035), however PPI alone
was not significantly associated with increased risk for hospitalization
(p=0.16).